Medipharm Labs Corp T.LABS

My completed Cannabis peer valuation table is posted

[deadlock]

Available at MicroCap.com/PDF - it is too large for here and I also cannot get images to display on this board. Most of the companies are drowning in debt while Cronos Group (CRON:TSX $3.35 / NASDAQ) & MediPharm Labs (LABS:TSX $0.07 / OTCQX) are "notably" attractive risk/reward. 

The table tracks the 19 primary players in this industry that are listed in Canada (several dual listed in the U.S.). Financials are current to the most recent publicly filed quarter. Table is sorted by EV to Sales multiple but also pay close attention to the columns showing (1) Market Cap to Adjusted Book Value (2) Enterprise Value and (3) Debt. As I noted last week, the heavy debt load for many of these companies is a glaring risk of further capital losses.

It is worth noting that the large majority of these companies have seen 90% of their share price eroded since Q1/21 when the sector peaked. And it is estimated investors have lost $130 BILLION on this sector over the past few years.

That being said... astute investors will look forward vs back and will recognize value here in select companies. The days of grossly over-valued acquisitions are over as is "growth at any cost". Now these companies must learn to turn a profit - or die.

[rejaj]

Thank you for the completed valuation table. As you note Labs is attractive from a risk reward ratio. Cronos has always caught my eye with nearly $ 1 billion in cash, but their expense to sales ratio seems stupid high at around 134%.  That ratio has always filtered them out of any of my own lists.  Seems like lackadaisical cost control although I'll admit I haven't looked in